title: Morphologic analysis in myelodysplastic syndromes with del(5q) treated with lenalidomide. A Japanese multiinstitutional study.
abstract: Lenalidomide is known to be effective in myelodysplastic syndromes (MDS) with del(5q) in improving anemia and suppressing del(5q) cells. MDS with del(5q) shows increase of nonlobulated megakaryocytes. However, histopathology of MDS with del(5q) treated with lenalidomide has not been fully studied. We investigated the morphologic changes in lenalidomide treated low- or intermediate-1-risk MDS with del(5q). All of evaluable patients showed high proportion of nonlobulated megakaryocytes. The nonlobulated megakaryocytes were markedly decreased in 6 patients during therapy in parallel with suppression of del(5q) cells. Our analysis suggests that single allele deletion of common deleted region inhibits nuclear lobulation of megakaryocytes.
authors.affiliation: Department of Hemato-Oncology, Saitama International Medical Center, Saitama Medical University, Saitama, Japan. amatsu@saitama-med.ac.jp
authors.forename: Akira
authors.initials: A
authors.lastname: Matsuda
authors.forename: Masafumi
authors.initials: M
authors.lastname: Taniwaki
authors.forename: Itsuro
authors.initials: I
authors.lastname: Jinnai
authors.forename: Hironori
authors.initials: H
authors.lastname: Harada
authors.forename: Mitsumasa
authors.initials: M
authors.lastname: Watanabe
authors.forename: Kenshi
authors.initials: K
authors.lastname: Suzuki
authors.forename: Soshi
authors.initials: S
authors.lastname: Yanagita
authors.forename: Takahiro
authors.initials: T
authors.lastname: Suzuki
authors.forename: Yataro
authors.initials: Y
authors.lastname: Yoshida
authors.forename: Akiro
authors.initials: A
authors.lastname: Kimura
authors.forename: Mitsuru
authors.initials: M
authors.lastname: Tsudo
authors.forename: Kaoru
authors.initials: K
authors.lastname: Tohyama
authors.forename: Masaaki
authors.initials: M
authors.lastname: Takatoku
authors.forename: Keiya
authors.initials: K
authors.lastname: Ozawa
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002872:Chromosome Deletion; D002895:Chromosomes, Human, Pair 5; D004920:Erythropoiesis / Q000187:drug effects; D006801:Humans; D000077269:Lenalidomide; D008533:Megakaryocytes / Q000187:drug effects / Q000473:pathology; D009190:Myelodysplastic Syndromes / Q000097:blood / Q000188:drug therapy / Q000235:genetics / Q000473:pathology*; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D013792:Thalidomide; D000077269:Lenalidomide